PMID- 36544625
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221223
IS  - 1745-1981 (Print)
IS  - 1740-4398 (Electronic)
IS  - 1740-4398 (Linking)
VI  - 11
DP  - 2022
TI  - Propranolol for the management of behavioural and psychological symptoms of 
      dementia.
LID - 10.7573/dic.2022-8-3 [doi]
LID - 2022-8-3
AB  - Propranolol is a beta-adrenergic antagonist used in the management of hypertension, 
      cardiac arrhythmia, and angina pectoris. There is some evidence that propranolol 
      may benefit individuals with behavioural and psychological symptoms of dementia 
      (BPSD). A total of three case series, one randomized controlled trial and one 
      case report were identified (from a literature search of three major databases: 
      PubMed, Ovid, and Cochrane collaboration) that assessed the use of propranolol 
      for the management of BPSD. From these studies, it appears that propranolol 
      improves BPSD, including agitation and aggression. Propranolol is also well 
      tolerated with no significant bradycardia or hypotension noted in these studies. 
      Current data on the use of propranolol for the management of BPSD are limited in 
      comparison to other pharmacological agents (atypical antipsychotics, 
      antidepressants, acetylcholinesterase inhibitors, memantine, and cannabinoids) 
      and treatment modalities (repetitive transcranial magnetic stimulation and 
      electroconvulsive therapy). The efficacy and safety of these treatments among 
      individuals with BPSD has been evaluated in multiple controlled studies. In 
      clinical practice, the routine use of propranolol among people with BPSD cannot 
      be recommended at this time given the limited data. However, propranolol can be 
      trialled among individuals with BPSD when symptoms have not responded adequately 
      to other medications. Propranolol may also be used prior to embarking on trials 
      of repetitive transcranial magnetic stimulation and electroconvulsive therapy 
      among people with BPSD given the greater acceptance of this medication in the 
      general population.
CI  - Copyright (c) 2022 Tampi RR, Tampi DJ, Farheen SA, Ochije SI, Joshi P.
FAU - Tampi, Rajesh R
AU  - Tampi RR
AD  - Department of Psychiatry, Creighton University School of Medicine, Omaha, NE, 
      USA.
AD  - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
AD  - Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, 
      Akron, OH, USA.
FAU - Tampi, Deena J
AU  - Tampi DJ
AD  - Co-Founder and Managing Principal, Behavioral Health Advisory Group, Princeton, 
      NJ, USA.
FAU - Farheen, Syeda Arshiya
AU  - Farheen SA
AD  - Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, 
      Akron, OH, USA.
FAU - Ochije, Sochima I
AU  - Ochije SI
AD  - Department of Psychiatry, Emory University Hospital, Atlanta GA, USA.
FAU - Joshi, Pallavi
AU  - Joshi P
AD  - Department of Psychiatry, University of Arizona College of Medicine-Phoenix, 
      Phoenix, AZ, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221208
PL  - England
TA  - Drugs Context
JT  - Drugs in context
JID - 101262187
PMC - PMC9753600
OTO - NOTNLM
OT  - aggression
OT  - agitation
OT  - behavioural and psychological symptoms of dementia
OT  - dementia
OT  - propranolol
OT  - randomized controlled trial (RCT)
COIS- Disclosure and potential conflicts of interest: The authors declare that they 
      have no conflicts of interest relevant to this manuscript. The International 
      Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests 
      form for the authors is available for download at: 
      https://www.drugsincontext.com/wp-content/uploads/2022/11/dic.2022-8-3-COI.pdf
EDAT- 2022/12/23 06:00
MHDA- 2022/12/23 06:01
PMCR- 2022/12/08
CRDT- 2022/12/22 02:18
PHST- 2022/08/25 00:00 [received]
PHST- 2022/10/26 00:00 [accepted]
PHST- 2022/12/22 02:18 [entrez]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2022/12/23 06:01 [medline]
PHST- 2022/12/08 00:00 [pmc-release]
AID - dic-2022-8-3 [pii]
AID - 10.7573/dic.2022-8-3 [doi]
PST - epublish
SO  - Drugs Context. 2022 Dec 8;11:2022-8-3. doi: 10.7573/dic.2022-8-3. eCollection 
      2022.